grant

Impact of novel activating antibodies targeting microglial TREM2 in a human triculture AD model

Organization UKRILocation United Kingdom
UKRIUK ResearchGrantActive
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Microglia, the immune cell of the brain, express the protein triggering receptor expressed on myeloid cells-2 (TREM2). Immune dysfunction linked to the microglial TREM2 R47Hhet variant increases late-onset Alzheimer's disease (LO-AD) risk, the most prevalent form of AD. TREM2 R47Hhet is a loss of function variant and TREM2 is a hub gene…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in United Kingdom🏷 More UKRI opportunities🏷 More UK Research opportunities🏷 More Grant opportunities🏢 All ukri_grants opportunities
Impact of novel activating antibodies targeting microglial TREM2 in a human triculture AD model — UKRI | United Kingdom | Dev Procure